Safety of a Live-Attenuated Japanese Encephalitis Virus Vaccine (SA14-14-2) for Children

Yu Yong XinNational Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China

Search for other papers by Yu Yong Xin in
Current site
Google Scholar
PubMed
Close
,
Zhang Guo MingNational Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China

Search for other papers by Zhang Guo Ming in
Current site
Google Scholar
PubMed
Close
,
Guo Yu PengNational Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China

Search for other papers by Guo Yu Peng in
Current site
Google Scholar
PubMed
Close
,
Ao JianNational Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China

Search for other papers by Ao Jian in
Current site
Google Scholar
PubMed
Close
, and
Li Ho MinNational Institute for the Control of Pharmaceutical and Biological Products, Beijing, People's Republic of China

Search for other papers by Li Ho Min in
Current site
Google Scholar
PubMed
Close
Restricted access

In a study begun in 1985, 1,026 children between the ages of 5 and 12 years, living in an area of low Japanese encephalitis (JE) infection, were vaccinated with live-attenuated JE vaccine, strain SA14-14-2. A group of 47 of the vaccinated children, 5–6 years of age, were examined for fever and other systemic reactions every other day for 2 weeks following vaccination. None of these children had temperatures >37.4°C or other systemic reactions during the observation period. No untoward reactions were reported in the remainder of the vaccinated group. After immunization, seroconversion rates in seronegative children were 100% (GMT 35.3, n = 11), 100% (GMT 31.7, n = 12), and 83.3% (GMT 23, n = 10) in groups receiving vaccine diluted 1:3, 1:5, and 1:50, respectively. These results indicate that the JE SA14-14-2 live-attenuated vaccine is immunogenic and safe for children.

Save